fda warning letter semaglutide october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Drug compounders sue FDA over

One argument compounders have made to defend their ability to make copy-cat products is that they are providing unique dosage forms (i.e., single-dose vials for self-administration vs

503B products are sold to healthcare facilities

The straightforward answer: semaglutide has a half-life of approximately seven days, meaning it takes about one week for half the dose to clear from your body

See our peptide reconstitution guide and the bacteriostatic water overview

Explore our collection of post-op guides for more insights, such as our detailed resource on neck lift and lower facelift recovery

Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist currently under clinical investigation and not licensed by the MHRA or EMA for use in the UK